• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分子吸附循环系统(MARS)治疗终末期肝硬化患者引起的急性全身、内脏和肾脏血流动力学变化

Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis.

作者信息

Donati G, Piscaglia F, Colì L, Silvagni E, Righini R, Donati G, Pini P, Stefoni S, Bolondi L

机构信息

Division of Internal Medicine, Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.

出版信息

Aliment Pharmacol Ther. 2007 Sep 1;26(5):717-26. doi: 10.1111/j.1365-2036.2007.03420.x.

DOI:10.1111/j.1365-2036.2007.03420.x
PMID:17697205
Abstract

AIM

To evaluate the acute effect of treatment with the molecular adsorbent recirculating system (MARS) on splanchnic, renal and systemic haemodynamics in patients with end-stage cirrhosis.

METHODS

Twelve patients with end-stage cirrhosis, undergoing MARS treatment, were enrolled. The following haemodynamic parameters were measured by means of Doppler ultrasonography and thoracic electrical bioimpedance, before and after each session: portal velocity, renal and splenic resistance indices, cardiac output, cardiac stroke volume, heart rate, mean arterial pressure, systemic vascular resistance.

RESULTS

Median portal velocity increased significantly after treatment (23.7 vs. 20.3 cm/s, P < 0.05) while renal resistance index (0.72 vs. 0.75, P < 0.05) and splenic resistance index (0.60 vs. 0.65, P < 0.05) decreased significantly. Mean arterial pressure (83 vs. 81 mmHg, P < 0.05) and vascular resistance (899 vs. 749 dyne. s/cm5, P < 0.05) increased significantly, while cardiac output and stroke volume showed no significant changes.

CONCLUSIONS

Data emerging from this investigation suggest that MARS treatment improves significantly various haemodynamic alterations in cirrhotic patients in the short term. The observed decrease in renal vascular resistance and improvement in splenic resistance index, a parameter related to portal resistance, which leads us to hypothesize that these haemodynamic effects are probably mediated by clearance of vasoactive substances during MARS treatment.

摘要

目的

评估分子吸附再循环系统(MARS)治疗对终末期肝硬化患者内脏、肾脏及全身血流动力学的急性影响。

方法

纳入12例接受MARS治疗的终末期肝硬化患者。在每次治疗前后,通过多普勒超声和胸部电阻抗法测量以下血流动力学参数:门静脉流速、肾和脾阻力指数、心输出量、心搏量、心率、平均动脉压、全身血管阻力。

结果

治疗后门静脉流速中位数显著增加(23.7对20.3 cm/s,P<0.05),而肾阻力指数(0.72对0.75,P<0.05)和脾阻力指数(0.60对0.65,P<0.05)显著降低。平均动脉压(83对81 mmHg,P<0.05)和血管阻力(899对749达因·秒/厘米⁵,P<0.05)显著增加,而心输出量和心搏量无显著变化。

结论

本研究得出的数据表明,MARS治疗在短期内可显著改善肝硬化患者的各种血流动力学改变。观察到的肾血管阻力降低和脾阻力指数改善,脾阻力指数是与门静脉阻力相关的参数,这使我们推测这些血流动力学效应可能是由MARS治疗期间血管活性物质的清除介导的。

相似文献

1
Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis.分子吸附循环系统(MARS)治疗终末期肝硬化患者引起的急性全身、内脏和肾脏血流动力学变化
Aliment Pharmacol Ther. 2007 Sep 1;26(5):717-26. doi: 10.1111/j.1365-2036.2007.03420.x.
2
Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure.慢性肝衰竭急性发作患者接受分子吸附再循环系统(MARS)治疗后的肝脏及全身血流动力学变化
Liver Int. 2003;23 Suppl 3:39-43. doi: 10.1034/j.1478-3231.23.s.3.10.x.
3
Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.分子吸附再循环系统在治疗肝硬化伴腹水且血管收缩剂治疗失败的 1 型肝肾综合征患者方面无效。
Gut. 2010 Mar;59(3):381-6. doi: 10.1136/gut.2008.174615. Epub 2009 Aug 25.
4
Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure.分子吸附循环系统和普乐可复装置对慢性酒精性肝衰竭急性发作患者全身血流动力学及血管活性药物的影响
Crit Care. 2006;10(4):R108. doi: 10.1186/cc4985.
5
Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study.肝硬化肝移植术后全身及内脏血流动力学变化:一项长期前瞻性研究。
Hepatology. 1999 Jul;30(1):58-64. doi: 10.1002/hep.510300112.
6
Duplex Doppler ultrasonography allows a multiorgan noninvasive approach to splanchnic pharmacodynamics in patients with cirrhosis.双功多普勒超声检查可为肝硬化患者提供一种多器官无创性内脏药效学研究方法。
Bildgebung. 1995 Jun;62(2):138-43.
7
Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure.慢性肝衰竭急性发作患者单次使用分子吸附循环系统治疗期间的血流动力学变化
Liver Transpl. 2001 Dec;7(12):1034-9. doi: 10.1053/jlts.2001.29108.
8
Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up.应用分子吸附再循环系统治疗肝衰竭的体外解毒:长期随访中的清除效率和临床结果。
Artif Organs. 2014 Feb;38(2):125-34. doi: 10.1111/aor.12106. Epub 2013 Jul 3.
9
Alterations in thyroid Doppler arterial resistance indices, volume and hormones in cirrhosis: relationships with splanchnic haemodynamics.
Ultrasound Med Biol. 2004 Jan;30(1):19-25. doi: 10.1016/j.ultrasmedbio.2003.10.008.
10
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial.应用分子吸附再循环系统的体外白蛋白透析治疗慢加急性肝衰竭:RELIEF 试验。
Hepatology. 2013 Mar;57(3):1153-62. doi: 10.1002/hep.26185. Epub 2013 Feb 15.

引用本文的文献

1
Extracorporeal organ support and the kidney.体外器官支持与肾脏
Front Nephrol. 2022 Aug 5;2:924363. doi: 10.3389/fneph.2022.924363. eCollection 2022.
2
The Efficacy of Albumin Dialysis in the Reversal of Refractory Vasoplegic Shock Due to Amlodipine Toxicity.白蛋白透析对氨氯地平中毒所致难治性血管麻痹性休克的疗效
Crit Care Explor. 2020 Jun 5;2(6):e0120. doi: 10.1097/CCE.0000000000000120. eCollection 2020 Jun.
3
Clinical value of urinary retinol-binding protein in ascites due to cirrhosis.尿视黄醇结合蛋白在肝硬化腹水患者中的临床价值
Exp Ther Med. 2017 Nov;14(5):5228-5234. doi: 10.3892/etm.2017.5190. Epub 2017 Sep 22.
4
Liver dialysis in acute-on-chronic liver failure: current and future perspectives.慢性肝衰竭急性发作时的肝透析:现状与未来展望
Hepatol Int. 2014 Sep;8 Suppl 2:505-13. doi: 10.1007/s12072-014-9534-8. Epub 2014 Apr 24.
5
Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis.全身炎症反应综合征与终末期肝病模型评分对肝硬化患者住院结局的影响
Middle East J Dig Dis. 2012 Jul;4(3):168-72.
6
The end-organ impairment in liver cirrhosis: appointments for critical care.肝硬化中的终末器官损害:重症监护要点
Crit Care Res Pract. 2012;2012:539412. doi: 10.1155/2012/539412. Epub 2012 May 16.
7
Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure.分子吸附再循环系统治疗急性肝衰竭的成本-效用分析。
World J Gastroenterol. 2010 May 14;16(18):2227-34. doi: 10.3748/wjg.v16.i18.2227.